Product attributes as listed by the labeler in the FDA NDC Directory.
Also searchable as: cyclophosphamide · cyclophosphamide anhydrous · Cyclophosphamide (Ingenus)
Drug codes appear here only when a CMS NDC–HCPCS crosswalk lists at least one of this drug’s NDC packages. CodeRx never assigns a code from the name or ingredient.
Cyclophosphamide; oral, 25 mg
Derived: 6 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J8530. CMS quarters Q1 2021 – Q4 2026
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
Package NDCs from the FDA directory, normalized to the 11-digit 5-4-2 format used on claims.
| 11-digit NDC | FDA NDC | Package description | Strength · form | Labeler | HCPCS · units / NDC | Status |
|---|---|---|---|---|---|---|
| 00054-0382-25 | 0054-0382-25 | 100 CAPSULE in 1 BOTTLE (0054-0382-25) | 25 mg/1Capsule | Hikma Pharmaceuticals USA Inc. | J8530 · 100 units |
One HCPCS billing unit of J8530
25 MG
Medicare payment limit per unit (Q4 2026): $1.233
One HCPCS billing unit of J9071
5 MG
Medicare payment limit per unit (Q4 2026): $0.471
One HCPCS billing unit of J9072
Medicare Part B payment limits for the codes above, then how the home infusion per diem S-codes are paid. Commercial payer rates, AWP, and WAC are not included.
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $1.233 | 25 MG | 20% | −17.3% |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Which Medicare benefit pays for this drug?
ICD-10-CM codes that Medicare contractors' Billing and Coding articles list as supporting medical necessity for this drug's HCPCS codes — covered diagnoses, not how often each is used. Washington (Noridian JF) articles come first; other contractors' articles are linked below.
No current Medicare Billing and Coding article lists J8530, J9071, J9072, J9073, J9074, J9075, C9087, J9070.
Quarterly changes to the HCPCS codes linked to this drug.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1995 |
| Quarterly file | Change | CMS action code | Details |
|---|
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
Injection, cyclophosphamide (auromedics), 5 mg
Derived: 5 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J9071. CMS quarters Q2 2022 – Q4 2026
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
Injection, cyclophosphamide (frindovyx), 5 mg
Derived: 3 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J9072. CMS quarters Q2 2025 – Q4 2026
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
Injection, cyclophosphamide (dr. reddy's), 5 mg
Derived: 5 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J9073. CMS quarters Q2 2024 – Q4 2026
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
Injection, cyclophosphamide (sandoz), 5 mg
Derived: 3 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J9074. CMS quarters Q4 2024 – Q4 2026
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
Injection, cyclophosphamide, not otherwise specified, 5 mg
Derived: 39 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J9075. CMS quarters Q2 2024 – Q4 2026
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
Injection, cyclophosphamide, (auromedics), 10 mg
Derived: 2 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for C9087. CMS quarters Q1 2022 – Q1 2022Not in the latest CMS crosswalk.
C-codes are temporary codes for hospital outpatient use under the Medicare Outpatient Prospective Payment System, including pass-through drugs and biologicals (many in C9xxx) and devices. They are generally not reported by physician offices; other payers may not recognize them.
Cyclophosphamide, 100 mg
Derived: 27 of 72 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J9070. CMS quarters Q1 2021 – Q1 2024Not in the latest CMS crosswalk.
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
When a home infusion pharmacy dispenses this drug, the drug is billed with the code above and each day of pharmacy services, supplies, and equipment with a per diem S-code. CMS publishes no drug-to-per-diem crosswalk, so CodeRx picks the therapy category from the FDA pharmacologic class and route. S-codes are not payable by Medicare; confirm the code against the payer contract.
No category matched · FDA class: No FDA pharmacologic class (EPC) listed
No specific category was found in this drug’s FDA pharmacologic class. Use a specific code instead when the therapy is one CodeRx cannot detect: hydration (S9373–S9377), tocolytic (S9349), anti-spasmodic (S9363), blood products (S9538), or irrigation (S9590).
| 00054-0383-25 | 0054-0383-25 | 100 CAPSULE in 1 BOTTLE (0054-0383-25) | 50 mg/1Capsule | Hikma Pharmaceuticals USA Inc. | J8530 · 200 units | Listed |
|---|
| 00781-3233-94 | 0781-3233-94 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0781-3233-94) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | Sandoz Inc. | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 00781-3244-94 | 0781-3244-94 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0781-3244-94) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | Sandoz Inc. | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 00781-3255-94 | 0781-3255-94 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0781-3255-94) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | Sandoz Inc. | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 00781-3528-10 | 0781-3528-10 | 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3528-10) / 5 mL in 1 VIAL, MULTI-DOSE (0781-3528-75) | 500 mg/5mLInjection, Solution, Concentrate | Sandoz Inc | J9074 · 100 units | Listed |
|---|
| 00781-3529-10 | 0781-3529-10 | 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3529-10) / 10 mL in 1 VIAL, MULTI-DOSE (0781-3529-70) | 1000 mg/10mLInjection, Solution, Concentrate | Sandoz Inc | J9074 · 200 units | Listed |
|---|
| 00781-3530-10 | 0781-3530-10 | 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3530-10) / 20 mL in 1 VIAL, MULTI-DOSE (0781-3530-80) | 2000 mg/20mLInjection, Solution, Concentrate | Sandoz Inc | J9074 · 400 units | Listed |
|---|
| 10019-0935-01 | 10019-935-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-935-01) / 25 mL in 1 VIAL, SINGLE-DOSE (10019-935-25) | 500 mg/25mLInjection, Powder, For Solution | Baxter Healthcare Company | J9070 · 5 units (Q1 2024)J9075 · 100 units (Q4 2024) | Listed |
|---|
| 10019-0936-01 | 10019-936-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-936-01) / 50 mL in 1 VIAL, SINGLE-DOSE (10019-936-50) | 1 g/50mLInjection, Powder, For Solution | Baxter Healthcare Company | J9070 · 10 units (Q1 2024)J9075 · 200 units (Q4 2024) | Listed |
|---|
| 10019-0937-01 | 10019-937-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-937-01) / 100 mL in 1 VIAL, SINGLE-DOSE (10019-937-10) | 2 g/100mLInjection, Powder, For Solution | Baxter Healthcare Company | J9070 · 20 units (Q1 2024)J9075 · 400 units (Q4 2024) | Listed |
|---|
| 10019-0938-01 | 10019-938-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-938-01) / 25 mL in 1 VIAL, SINGLE-DOSE (10019-938-25) | 500 mg/25mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 10019-0939-01 | 10019-939-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-939-01) / 50 mL in 1 VIAL, SINGLE-DOSE (10019-939-50) | 1 g/50mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 10019-0942-01 | 10019-942-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-942-01) / 100 mL in 1 VIAL, SINGLE-DOSE (10019-942-10) | 2 g/100mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 10019-0943-01 | 10019-943-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-943-01) / 25 mL in 1 VIAL, SINGLE-DOSE (10019-943-25) | 500 mg/25mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 10019-0944-01 | 10019-944-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-944-01) / 50 mL in 1 VIAL, SINGLE-DOSE (10019-944-50) | 1 g/50mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 10019-0945-01 | 10019-945-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-945-01) / 100 mL in 1 VIAL, SINGLE-DOSE (10019-945-10) | 2 g/100mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 10019-0955-01 | 10019-955-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-955-01) / 25 mL in 1 VIAL, SINGLE-DOSE (10019-955-50) | 500 mg/25mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 10019-0956-01 | 10019-956-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-956-01) / 50 mL in 1 VIAL, SINGLE-DOSE (10019-956-16) | 1 g/50mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 10019-0957-01 | 10019-957-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-957-01) / 100 mL in 1 VIAL, SINGLE-DOSE (10019-957-11) | 2 g/100mLInjection, Powder, For Solution | Baxter Healthcare Company | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 10019-0982-01 | 10019-982-01 | 1 BOTTLE in 1 CARTON (10019-982-01) / 100 TABLET in 1 BOTTLE (10019-982-09) | 25 mg/1Tablet | Baxter Healthcare Corporation | J8530 · 100 units (Q1 2025) | Listed |
|---|
| 10019-0984-01 | 10019-984-01 | 1 BOTTLE in 1 CARTON (10019-984-01) / 100 TABLET in 1 BOTTLE (10019-984-09) | 50 mg/1Tablet | Baxter Healthcare Corporation | J8530 · 200 units | Listed |
|---|
| 14789-0125-05 | 14789-125-05 | 1 VIAL, GLASS in 1 CARTON (14789-125-05) / 2.5 mL in 1 VIAL, GLASS (14789-125-07) | 200 mg/mLInjection | Nexus Pharmaceuticals, LLC | Not in CMS crosswalk | Listed |
|---|
| 14789-0126-05 | 14789-126-05 | 1 VIAL, GLASS in 1 CARTON (14789-126-05) / 5 mL in 1 VIAL, GLASS (14789-126-07) | 200 mg/mLInjection | Nexus Pharmaceuticals, LLC | Not in CMS crosswalk | Listed |
|---|
| 16714-0857-01 | 16714-857-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (16714-857-01) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | NorthStar Rx LLC | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 16714-0858-01 | 16714-858-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (16714-858-01) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | NorthStar Rx LLC | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 16714-0859-01 | 16714-859-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (16714-859-01) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | NorthStar Rx LLC | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 25021-0247-50 | 25021-247-50 | 1 VIAL in 1 CARTON (25021-247-50) / 25 mL in 1 VIAL | 500 mg/25mLInjection, Powder, Lyophilized, For Solution | Sagent Pharmaceuticals | J9075 · 100 units | Listed |
|---|
| 25021-0248-51 | 25021-248-51 | 1 VIAL in 1 CARTON (25021-248-51) / 50 mL in 1 VIAL | 1 g/50mLInjection, Powder, Lyophilized, For Solution | Sagent Pharmaceuticals | J9075 · 200 units | Listed |
|---|
| 25021-0249-51 | 25021-249-51 | 1 VIAL in 1 CARTON (25021-249-51) / 100 mL in 1 VIAL | 2 g/100mLInjection, Powder, Lyophilized, For Solution | Sagent Pharmaceuticals | J9075 · 400 units | Listed |
|---|
| 39822-0250-01 | 39822-0250-1 | 1 VIAL, SINGLE-DOSE in 1 CARTON (39822-0250-1) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, Lyophilized, For Solution | XGen Pharmaceuticals DJB, Inc. | J9075 · 100 units | Listed |
|---|
| 39822-0255-01 | 39822-0255-1 | 1 VIAL, SINGLE-DOSE in 1 CARTON (39822-0255-1) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, Lyophilized, For Solution | XGen Pharmaceuticals DJB, Inc. | J9075 · 200 units | Listed |
|---|
| 39822-0260-01 | 39822-0260-1 | 1 VIAL, SINGLE-DOSE in 1 CARTON (39822-0260-1) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, Lyophilized, For Solution | XGen Pharmaceuticals DJB, Inc. | J9075 · 400 units | Listed |
|---|
| 42806-0901-26 | 42806-901-26 | 1 VIAL, SINGLE-DOSE in 1 CARTON (42806-901-26) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | Epic Pharma, LLC | Not in CMS crosswalk | Listed |
|---|
| 42806-0902-26 | 42806-902-26 | 1 VIAL, SINGLE-DOSE in 1 CARTON (42806-902-26) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | Epic Pharma, LLC | Not in CMS crosswalk | Listed |
|---|
| 42806-0903-26 | 42806-903-26 | 1 VIAL, SINGLE-DOSE in 1 CARTON (42806-903-26) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | Epic Pharma, LLC | Not in CMS crosswalk | Listed |
|---|
| 55150-0270-01 | 55150-270-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-270-01) / 2.5 mL in 1 VIAL, SINGLE-DOSE | 500 mg/2.5mLInjection | Eugia US LLC | C9087 · 50 units (Q1 2022)J9071 · 100 units (Q3 2026) | Discontinued by the firm (D) |
|---|
| 55150-0270-99 | 55150-270-99 | 1 VIAL, MULTI-DOSE in 1 CARTON (55150-270-99) / 2.5 mL in 1 VIAL, MULTI-DOSE | 500 mg/2.5mLInjection | Eugia US LLC | J9071 · 100 units | Listed |
|---|
| 55150-0271-01 | 55150-271-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-271-01) / 5 mL in 1 VIAL, SINGLE-DOSE | 1 g/5mLInjection | Eugia US LLC | C9087 · 100 units (Q1 2022)J9071 · 200 units (Q3 2026) | Discontinued by the firm (D) |
|---|
| 55150-0271-99 | 55150-271-99 | 1 VIAL, MULTI-DOSE in 1 CARTON (55150-271-99) / 5 mL in 1 VIAL, MULTI-DOSE | 1 g/5mLInjection | Eugia US LLC | J9071 · 200 units | Listed |
|---|
| 55150-0272-01 | 55150-272-01 | 1 VIAL, MULTI-DOSE in 1 CARTON (55150-272-01) / 10 mL in 1 VIAL, MULTI-DOSE | 2 g/10mLInjection | Eugia US LLC | J9071 · 400 units | Listed |
|---|
| 65219-0131-20 | 65219-131-20 | 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-131-20) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | Fresenius Kabi USA, LLC | J9075 · 200 units | Listed |
|---|
| 65219-0133-20 | 65219-133-20 | 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-133-20) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | Fresenius Kabi USA, LLC | J9075 · 400 units | Listed |
|---|
| 65219-0135-20 | 65219-135-20 | 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-135-20) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | Fresenius Kabi USA, LLC | J9075 · 100 units | Listed |
|---|
| 68001-0442-26 | 68001-442-26 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-442-26) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | BluePoint Laboratories | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 68001-0443-27 | 68001-443-27 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-443-27) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | BluePoint Laboratories | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 68001-0444-32 | 68001-444-32 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-444-32) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | BluePoint Laboratories | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 68001-0564-22 | 68001-564-22 | 1 VIAL in 1 CARTON (68001-564-22) / 5 mL in 1 VIAL | 200 mg/mLInjection, Solution | BluePoint Laboratories | J9073 · 200 units | Listed |
|---|
| 68001-0565-28 | 68001-565-28 | 1 VIAL in 1 CARTON (68001-565-28) / 10 mL in 1 VIAL | 200 mg/mLInjection, Solution | BluePoint Laboratories | J9073 · 400 units | Listed |
|---|
| 68001-0694-27 | 68001-694-27 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-694-27) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | BluePoint Laboratories | J9075 · 100 units | Listed |
|---|
| 68001-0695-32 | 68001-695-32 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-695-32) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | BluePoint Laboratories | J9075 · 200 units | Listed |
|---|
| 68001-0696-32 | 68001-696-32 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-696-32) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | BluePoint Laboratories | J9075 · 400 units | Listed |
|---|
| 69097-0516-07 | 69097-516-07 | 100 CAPSULE in 1 BOTTLE (69097-516-07) | 25 mg/1Capsule | Cipla USA Inc. | J8530 · 100 units | Listed |
|---|
| 69097-0517-07 | 69097-517-07 | 100 CAPSULE in 1 BOTTLE (69097-517-07) | 50 mg/1Capsule | Cipla USA Inc. | J8530 · 200 units | Listed |
|---|
| 70121-1238-01 | 70121-1238-1 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70121-1238-1) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | Amneal Pharmaceuticals LLC | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 70121-1239-01 | 70121-1239-1 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70121-1239-1) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | Amneal Pharmaceuticals LLC | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 70121-1240-01 | 70121-1240-1 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70121-1240-1) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | Amneal Pharmaceuticals LLC | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 72572-0083-01 | 72572-083-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (72572-083-01) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | Civica, Inc. | J9075 · 400 unitsJ9070 · 20 units (Q1 2024) | Listed |
|---|
| 72572-0085-01 | 72572-085-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (72572-085-01) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | Civica, Inc. | J9075 · 200 unitsJ9070 · 10 units (Q1 2024) | Listed |
|---|
| 72572-0087-01 | 72572-087-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (72572-087-01) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | Civica, Inc. | J9075 · 100 unitsJ9070 · 5 units (Q1 2024) | Listed |
|---|
| 75907-0189-35 | 75907-189-35 | 1 VIAL in 1 CARTON (75907-189-35) / 10 mL in 1 VIAL | 200 mg/mLInjection, Solution | Dr. Reddy's Labratories Inc. | J9073 · 400 units | Listed |
|---|
| 75907-0190-07 | 75907-190-07 | 1 VIAL in 1 CARTON (75907-190-07) / 5 mL in 1 VIAL | 200 mg/mLInjection, Solution | Dr. Reddy's Labratories Inc. | J9073 · 200 units | Listed |
|---|
| 75907-0191-02 | 75907-191-02 | 1 VIAL in 1 CARTON (75907-191-02) / 2.5 mL in 1 VIAL | 200 mg/mLInjection, Solution | Dr. Reddy's Labratories Inc. | J9073 · 100 units | Listed |
|---|
| 83634-0205-50 | 83634-205-50 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83634-205-50) / 25 mL in 1 VIAL, SINGLE-DOSE | 500 mg/25mLInjection, Powder, For Solution | Avenacy, LLC | Not in CMS crosswalk | Listed |
|---|
| 83634-0206-51 | 83634-206-51 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83634-206-51) / 50 mL in 1 VIAL, SINGLE-DOSE | 1 g/50mLInjection, Powder, For Solution | Avenacy, LLC | Not in CMS crosswalk | Listed |
|---|
| 83634-0207-51 | 83634-207-51 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83634-207-51) / 100 mL in 1 VIAL, SINGLE-DOSE | 2 g/100mLInjection, Powder, For Solution | Avenacy, LLC | Not in CMS crosswalk | Listed |
|---|
| 83703-0549-01 | 83703-549-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83703-549-01) / 25 mL in 1 VIAL, SINGLE-DOSE (83703-549-25) | 500 mg/25mLInjection, Powder, For Solution | Bamboo US Bidco LCC | Not in CMS crosswalk | Listed |
|---|
| 83703-0550-01 | 83703-550-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83703-550-01) / 50 mL in 1 VIAL, SINGLE-DOSE (83703-550-50) | 1 g/50mLInjection, Powder, For Solution | Bamboo US Bidco LCC | Not in CMS crosswalk | Listed |
|---|
| 83703-0551-01 | 83703-551-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83703-551-01) / 100 mL in 1 VIAL, SINGLE-DOSE (83703-551-10) | 2 g/100mLInjection, Powder, For Solution | Bamboo US Bidco LCC | Not in CMS crosswalk | Listed |
|---|
| 83831-0116-01 | 83831-116-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83831-116-01) / 1 mL in 1 VIAL, SINGLE-DOSE | 500 mg/mLInjection | Avyxa Pharma, LLC | J9072 · 100 units | Listed |
|---|
| 83831-0117-02 | 83831-117-02 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83831-117-02) / 2 mL in 1 VIAL, SINGLE-DOSE | 1 g/2mLInjection | Avyxa Pharma, LLC | J9072 · 200 units | Listed |
|---|
| 83831-0118-04 | 83831-118-04 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83831-118-04) / 4 mL in 1 VIAL, SINGLE-DOSE | 2 g/4mLInjection | Avyxa Pharma, LLC | J9072 · 400 units | Listed |
|---|
5 MG
Medicare payment limit per unit (Q4 2026): $8.120
One HCPCS billing unit of J9073
5 MG
Medicare payment limit per unit (Q4 2026): $0.465
One HCPCS billing unit of J9074
5 MG
Medicare payment limit per unit (Q4 2026): $3.238
One HCPCS billing unit of J9075
5 MG
Medicare payment limit per unit (Q4 2026): $0.692
Billable units per package for each NDC are listed in the NDC packages table above (CMS “BILLUNITSPKG”).
| — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $1.491 | 25 MG | 20% | −9.6% | — |
|---|
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $1.649 | 25 MG | 20% | −9.3% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $1.819 | 25 MG | 20% | +65.8% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $1.097 | 25 MG | 20% | −44.7% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.982 | 25 MG | 20% | +74.0% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.139 | 25 MG | 20% | +36.2% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.836 | 25 MG | 20% | −5.3% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.883 | 25 MG | 20% | −8.2% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.962 | 25 MG | 20% | +12.0% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.859 | 25 MG | 20% | +39.0% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $0.618 | 25 MG | 20% | −38.6% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $1.006 | 25 MG | 20% | +5.6% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $0.953 | 25 MG | 20% | +6.5% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $0.895 | 25 MG | 20% | +33.0% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $0.673 | 25 MG | — | +15.6% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $0.582 | 25 MG | — | −22.9% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.755 | 25 MG | — | −22.8% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $0.978 | 25 MG | — | +10.6% | AMP-based payment limit |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.884 | 25 MG | — | +9.7% | AMP-based payment limit |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.806 | 25 MG | — | −29.5% | AMP-based payment limit |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $1.143 | 25 MG | — | −22.1% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $1.467 | 25 MG | — | −9.6% | AMP-based payment limit; Updated April 2022 |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $1.623 | 25 MG | — | — | — |
|---|
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.471 | 5 MG | 20% | −3.9% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.490 | 5 MG | 20% | −5.6% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.519 | 5 MG | 20% | −14.4% | — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.606 | 5 MG | 20% | −3.8% | — |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.630 | 5 MG | 20% | −19.6% | — |
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.784 | 5 MG | 20% | −9.8% | — |
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.869 | 5 MG | 20% | +24.1% | AMP-based payment limit |
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.700 | 5 MG | 20% | −39.7% | AMP-based payment limit |
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $1.160 | 5 MG | 20% | −7.5% | — |
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $1.254 | 5 MG | 20% | −28.6% | — |
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $1.757 | 5 MG | 20% | −1.9% | — |
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $1.791 | 5 MG | 20% | −8.2% | — |
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $1.952 | 5 MG | 20% | +64.4% | Updated January 2024 |
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $1.187 | 5 MG | 20% | −69.3% | Updated October 2023 |
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $3.869 | 5 MG | 20% | +8.3% | — |
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $3.574 | 5 MG | — | +29.8% | — |
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $2.753 | 5 MG | — | — | Added October 2022 |
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $8.120 | 5 MG | 20% | −9.0% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $8.922 | 5 MG | 20% | −2.0% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $9.103 | 5 MG | 20% | +1.2% | — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $8.991 | 5 MG | 9.037% | −1.3% | Inflation-adjusted coinsurance |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $9.105 | 5 MG | 20% | +1.1% | — |
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $9.003 | 5 MG | 20% | −0.6% | — |
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $9.053 | 5 MG | 20% | — | Added April 2025 |
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.465 | 5 MG | 20% | −6.6% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.498 | 5 MG | 20% | −1.0% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.503 | 5 MG | 20% | −27.7% | — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.696 | 5 MG | 20% | −11.2% | — |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.784 | 5 MG | 20% | −32.2% | AMP-based payment limit |
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.156 | 5 MG | 20% | −34.4% | — |
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.762 | 5 MG | 20% | −19.5% | — |
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $2.188 | 5 MG | 17.035% | +136.5% | Inflation-adjusted coinsurance |
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.925 | 5 MG | 20% | +17.2% | — |
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.789 | 5 MG | 20% | −19.6% | — |
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.981 | 5 MG | 20% | — | Added April 2024 |
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $3.238 | 5 MG | 20% | −5.8% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $3.438 | 5 MG | 20% | −5.9% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $3.653 | 5 MG | 20% | −4.9% | — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $3.841 | 5 MG | 20% | −2.4% | — |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $3.936 | 5 MG | 20% | −6.5% | — |
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $4.210 | 5 MG | 20% | −3.1% | — |
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $4.344 | 5 MG | 20% | −0.2% | — |
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $4.351 | 5 MG | 20% | — | Added January 2025 |
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.692 | 5 MG | 20% | +20.3% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.575 | 5 MG | 20% | −25.6% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.773 | 5 MG | 20% | +32.1% | — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.585 | 5 MG | 20% | +21.6% | — |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.481 | 5 MG | 20% | −22.9% | — |
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.624 | 5 MG | 20% | −21.9% | — |
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.799 | 5 MG | 20% | −8.8% | — |
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.876 | 5 MG | 20% | −13.3% | — |
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $1.010 | 5 MG | 20% | −8.7% | — |
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $1.106 | 5 MG | 20% | +20.5% | — |
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.918 | 5 MG | 20% | — | Added April 2024 |
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $20.153 | 100 MG | 20% | +12.3% | — |
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $17.942 | 100 MG | 20% | +5.0% | — |
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $17.087 | 100 MG | 20% | −21.0% | — |
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $21.637 | 100 MG | 20% | −2.2% | — |
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $22.131 | 100 MG | — | +0.9% | — |
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $21.923 | 100 MG | — | −18.4% | — |
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $26.870 | 100 MG | — | +12.5% | — |
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $23.880 | 100 MG | — | −13.1% | — |
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $27.473 | 100 MG | — | −5.8% | — |
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $29.153 | 100 MG | — | −5.9% | — |
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $30.997 | 100 MG | — | +0.4% | — |
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $30.888 | 100 MG | — | −0.9% | — |
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $31.164 | 100 MG | — | — | — |
| Code | Description (CMS) | Max fee · Non-rural | Max fee · Rural | PA / EPA | HCA comments |
|---|---|---|---|---|---|
| A4220 | Infusion pump refill kit | $24.61 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
| A4221 | Supp non-insulin inf cath/wk | $24.96 | N/A | — | — |
| A4222 | Infusion supplies with pump | $47.35 | N/A | — | — |
| A4223 | Infusion supplies w/o pump | BR* | N/A | — | *Please see 2nd Tab for Requirements |
Maximum allowable fees as published by HCA, per billing unit of each code. BR = by report (invoice required); DP = covered under another program (see comments); N/A = no separate rate for that area. HCA pays the lesser of the provider’s usual charge and the maximum allowable fee (WAC 182-553).
How Medicare pays for home infusion instead
Medicare pays no per diem. Under its home infusion therapy services benefit, a qualified home infusion supplier is paid per infusion day, and only for drugs given through a Medicare-covered external infusion pump:
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
| Q2 2024 | Descriptor changed | B — Administrative data field and long description changed | Now: Injection, cyclophosphamide (auromedics), 5 mgBefore: Injection, cyclophosphamide, (auromedics), 5 mg |
|---|---|---|---|
| Q2 2024 | Dates changed | B — Administrative data field and long description changed | Added Apr 1, 2022 · action effective Apr 1, 2024 · termination — |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Apr 1, 2022 |
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q4 2025 | Descriptor changed | C — Long description changed | Now: Injection, cyclophosphamide (frindovyx), 5 mgBefore: Injection, cyclophosphamide (avyxa), 5 mg |
| Q4 2025 | Dates changed | C — Long description changed | Added Jan 1, 2024 · action effective Oct 1, 2025 · termination — |
| Q1 2025 | Descriptor changed | C — Long description changed | Now: Injection, cyclophosphamide (avyxa), 5 mgBefore: Injection, cyclophosphamide (dr. reddy's), 5 mg |
| Q1 2025 | Dates changed | C — Long description changed | Added Jan 1, 2024 · action effective Jan 1, 2025 · termination — |
| Q2 2024 | Dates changed | B — Administrative data field and long description changed | Added Jan 1, 2024 · action effective Apr 1, 2024 · termination — |
| Q2 2024 | Descriptor changed | B — Administrative data field and long description changed | Now: Injection, cyclophosphamide (dr. reddy's), 5 mgBefore: Injection, cyclophosphamide, (dr. reddy's), 5 mg |
| Q1 2024 | Added to HCPCS | A — Added | Added date Jan 1, 2024 |
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2025 | Descriptor changed | C — Long description changed | Now: Injection, cyclophosphamide (dr. reddy's), 5 mgBefore: Injection, cyclophosphamide (ingenus), 5 mg |
| Q2 2025 | Dates changed | C — Long description changed | Added Apr 1, 2024 · action effective Apr 1, 2025 · termination — |
| Q2 2024 | Added to HCPCS | A — Added | Added date Apr 1, 2024 |
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2024 | Added to HCPCS | A — Added | Added date Apr 1, 2024 |
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2024 | Added to HCPCS | A — Added | Added date Apr 1, 2024 |
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2022 |
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2024 | Termination date set | D — Discontinued | Termination date Mar 31, 2024 |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1984 |
Every import with its checksum is listed on the data sources page.
| A4224 | Supply insulin inf cath/wk | $24.96 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4225 | Sup/ext insulin inf pump syr | $3.35 | N/A | — | — |
|---|
| A4230 | Infus insulin pump non needl | $201.45 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4231 | Infusion insulin pump needle | $134.29 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4232 | Syringe w/needle insulin 3cc | $79.14 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4238 | Adju cgm supply allowance | $270.89 | N/A | EPA | Invoice Required/See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4239 | Non-adju cgm supply allow | $263.72 | N/A | EPA | Limit: 1 unit/month - See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4246 | Betadine/phisohex solution | $2.87 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4247 | Betadine/iodine swabs/wipes | $4.55 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4602 | Replace lithium battery 1.5v | $5.31 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A4927 | Non-sterile gloves | DP | N/A | PA - Exceptions to Max | Please see Medical Equipment Fee Schedule for rates |
|---|
| A4930 | Sterile, gloves per pair | DP | N/A | — | Please see Medical Equipment Fee Schedule for rates |
|---|
| A9276 | Disposable sensor, cgm sys | BR | N/A | PA/EPA | Invoice Required/See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| A9277 | External transmitter, cgm | BR | N/A | PA/EPA | invoice required |
|---|
| A9278 | External receiver, cgm sys | BR | N/A | PA/EPA | Invoice Required/See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| B4164 | Parenteral 50% dextrose solu | $18.8947 | N/A | — | — |
|---|
| B4168 | Parenteral sol amino acid 3. | $27.5508 | N/A | — | — |
|---|
| B4172 | Parenteral sol amino acid 5. | $31.74 | N/A | — | — |
|---|
| B4176 | Parenteral sol amino acid 7- | $53.3162 | N/A | — | — |
|---|
| B4178 | Parenteral sol amino acid > | $63.9988 | N/A | — | — |
|---|
| B4180 | Parenteral sol carb > 50% | $27.1261 | N/A | — | — |
|---|
| B4185 | Pn soln nos 10 grams lipids | $12.4967 | N/A | — | — |
|---|
| B4189 | Parenteral sol amino acid & | $197.7092 | N/A | — | — |
|---|
| B4193 | Parenteral sol 52-73 gm prot | $255.4644 | N/A | — | — |
|---|
| B4197 | Parenteral sol 74-100 gm pro | $311.0195 | N/A | — | — |
|---|
| B4199 | Parenteral sol > 100gm prote | $355.3902 | N/A | — | — |
|---|
| B4216 | Parenteral nutrition additiv | $8.5885 | N/A | — | — |
|---|
| B4220 | Parenteral supply kit premix | $8.907 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| B4222 | Parenteral supply kit homemi | $10.9817 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| B4224 | Parenteral administration ki | $27.8113 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| B5000 | Parenteral sol renal-amirosy | $13.2205 | N/A | — | — |
|---|
| B5100 | Parenteral solution hepatic | $5.1627 | N/A | — | — |
|---|
| B9004-NU | Parenteral infus pump portab | $2,806.3937 | N/A | — | — |
|---|
| B9004-RR | Parenteral infus pump portab | $444.257 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| B9006-NU | Parenteral infus pump statio | $2,806.3937 | N/A | — | — |
|---|
| B9006-RR | Parenteral infus pump statio | $444.257 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| B9999 | Parenteral supp not othrws c | BR | N/A | PA | invoice required |
|---|
| E0776-NU | Iv pole | $177.29 | N/A | — | — |
|---|
| E0776-RR | Iv pole | $17.73 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| E0779-RR | Amb infusion pump mechanical | $23.00 | $23.00 | — | — |
|---|
| E0780-NU | Mech amb infusion pump <8hrs | $14.26 | N/A | — | — |
|---|
| E0781-RR | External ambulatory infus pu | $298.50 | $331.38 | — | — |
|---|
| E0784-RR | Ext amb infusn pump insulin | $538.23 | $556.19 | PA | For Omnipod See Pharmacy Benefit/See Home Infusion & Parenteral Nutrion Billing Guide fo rDetails |
|---|
| E0791-RR | Parenteral infusion pump sta | $354.62 | $394.73 | — | — |
|---|
| E1399 | Durable medical equipment mi | BR | N/A | PA | Invoice Required |
|---|
| E2102-NU | Adju cgm receiver/monitor | $226.32 | N/A | EPA | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| E2102-RR | Adju cgm receiver/monitor | $22.63 | N/A | EPA | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| E2102-UE | Adju cgm receiver/monitor | $169.75 | N/A | EPA | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| E2103 | Non-adju cgm receiver/mon | $290.73 | N/A | EPA | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| K0601 | Repl batt silver oxide 1.5 v | $1.52 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| K0602 | Repl batt silver oxide 3 v | $8.57 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| K0603 | Repl batt alkaline 1.5 v | $0.77 | N/A | — | See Home Infusion & Parenteral Nutrition Billing Guide for Details |
|---|
| K0604 | Repl batt lithium 3.6 v | $8.26 | N/A | — | — |
|---|
| K0605 | Repl batt lithium 4.5 v | $19.73 | N/A | — | — |
|---|
| K0739 | Repair/svc dme non-oxygen eq | $30.90 | N/A | PA | — |
|---|